(Q41686477)

English

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients

scientific article published on September 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rima Kulkarni

1

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Michael E Abram

2

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Damian J McColl

3

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Tiffany Barnes

4

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Marshall W Fordyce

5

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Javier Szwarcberg

6

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Andrew K Cheng

7

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Michael D Miller

8

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Kirsten L White

9

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

publication date

1 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

218-230

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1505-218

21 January 2018

Identifiers

10.1310/HCT1505-218

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41686477&oldid=1925904216"